Do ex­ec de­par­tures por­tend clin­i­cal dis­as­ters? An­a­lyst counts the ex­am­ples

For many biotech ob­servers, small cor­po­rate news can mean big things. Can­cel­la­tion of a sched­uled in­vestor pre­sen­ta­tion, halt­ing of a stock and tri­al switch-ups can all pique in­vestors’ in­ter­est. Most of all, ex­ec­u­tive de­par­tures — es­pe­cial­ly ahead of late-stage clin­i­cal da­ta — are of­ten con­strued as a sign of doom.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER